317 related articles for article (PubMed ID: 22118000)
1. Serum hepcidin in haemodialysis patients: associations with iron status and microinflammation.
Xu Y; Ding XQ; Zou JZ; Liu ZH; Jiang SH; Chen YM
J Int Med Res; 2011; 39(5):1961-7. PubMed ID: 22118000
[TBL] [Abstract][Full Text] [Related]
2. Serum hepcidin levels in patients with end-stage renal disease on hemodialysis.
Rubab Z; Amin H; Abbas K; Hussain S; Ullah MI; Mohsin S
Saudi J Kidney Dis Transpl; 2015 Jan; 26(1):19-25. PubMed ID: 25579711
[TBL] [Abstract][Full Text] [Related]
3. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients.
Costa E; Swinkels DW; Laarakkers CM; Rocha-Pereira P; Rocha S; Reis F; Teixeira F; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
Acta Haematol; 2009; 122(4):226-9. PubMed ID: 19887781
[No Abstract] [Full Text] [Related]
4. Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA.
Peters HP; Rumjon A; Bansal SS; Laarakkers CM; van den Brand JA; Sarafidis P; Musto R; Malyszko J; Swinkels DW; Wetzels JF; Macdougall IC
Nephrol Dial Transplant; 2012 Oct; 27(10):3923-9. PubMed ID: 22815544
[TBL] [Abstract][Full Text] [Related]
5. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients.
Zaritsky J; Young B; Gales B; Wang HJ; Rastogi A; Westerman M; Nemeth E; Ganz T; Salusky IB
Clin J Am Soc Nephrol; 2010 Jun; 5(6):1010-4. PubMed ID: 20299375
[TBL] [Abstract][Full Text] [Related]
6. Systemic inflammation up-regulates serum hepcidin in exacerbations and stabile chronic obstructive pulmonary disease.
Tandara L; Grubisic TZ; Ivan G; Jurisic Z; Tandara M; Gugo K; Mladinov S; Salamunic I
Clin Biochem; 2015 Dec; 48(18):1252-7. PubMed ID: 26164540
[TBL] [Abstract][Full Text] [Related]
7. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents.
van der Weerd NC; Grooteman MP; Bots ML; van den Dorpel MA; den Hoedt CH; Mazairac AH; Nubé MJ; Penne EL; Gaillard CA; Wetzels JF; Wiegerinck ET; Swinkels DW; Blankestijn PJ; Ter Wee PM;
PLoS One; 2012; 7(7):e39783. PubMed ID: 22808058
[TBL] [Abstract][Full Text] [Related]
8. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy.
Weiss G; Theurl I; Eder S; Koppelstaetter C; Kurz K; Sonnweber T; Kobold U; Mayer G
Eur J Clin Invest; 2009 Oct; 39(10):883-90. PubMed ID: 19563467
[TBL] [Abstract][Full Text] [Related]
9. Hepcidin and inflammatory bowel disease: dual role in host defence and iron homoeostasis.
Arnold J; Sangwaiya A; Bhatkal B; Geoghegan F; Busbridge M
Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):425-9. PubMed ID: 19262400
[TBL] [Abstract][Full Text] [Related]
10. HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients.
Valenti L; Girelli D; Valenti GF; Castagna A; Como G; Campostrini N; Rametta R; Dongiovanni P; Messa P; Fargion S
Clin J Am Soc Nephrol; 2009 Aug; 4(8):1331-7. PubMed ID: 19541813
[TBL] [Abstract][Full Text] [Related]
11. Possible relationship between neutrophil gelatinase-associated lipocalin, hepcidin, and inflammation in haemodialysed patients.
Malyszko J; Malyszko JS; Kozminski P; Koc-Zorawska E; Mysliwiec M; Macdougall I
Nephron Clin Pract; 2010; 115(4):c268-75. PubMed ID: 20424477
[TBL] [Abstract][Full Text] [Related]
12. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
[TBL] [Abstract][Full Text] [Related]
13. Hepcidin--a potential novel biomarker for iron status in chronic kidney disease.
Zaritsky J; Young B; Wang HJ; Westerman M; Olbina G; Nemeth E; Ganz T; Rivera S; Nissenson AR; Salusky IB
Clin J Am Soc Nephrol; 2009 Jun; 4(6):1051-6. PubMed ID: 19406957
[TBL] [Abstract][Full Text] [Related]
14. Impact of serum hepcidin and inflammatory markers on resistance to erythropoiesis-stimulating therapy in haemodialysis patients.
El Sewefy DA; Farweez BA; Behairy MA; Yassin NR
Int Urol Nephrol; 2019 Feb; 51(2):325-334. PubMed ID: 30600440
[TBL] [Abstract][Full Text] [Related]
15. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents.
Tessitore N; Girelli D; Campostrini N; Bedogna V; Pietro Solero G; Castagna A; Melilli E; Mantovani W; De Matteis G; Olivieri O; Poli A; Lupo A
Nephrol Dial Transplant; 2010 Dec; 25(12):3996-4002. PubMed ID: 20538788
[TBL] [Abstract][Full Text] [Related]
16. Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients.
Ford BA; Eby CS; Scott MG; Coyne DW
Kidney Int; 2010 Oct; 78(8):769-73. PubMed ID: 20668427
[TBL] [Abstract][Full Text] [Related]
17. Iron metabolism, hepcidin, and anemia in orthotopic heart transplantation recipients treated with mammalian target of rapamycin.
Przybylowski P; Malyszko JS; Macdougall IC; Malyszko J
Transplant Proc; 2013; 45(1):387-90. PubMed ID: 23375326
[TBL] [Abstract][Full Text] [Related]
18. Hepcidin concentrations and iron homeostasis in preeclampsia.
Toldi G; Stenczer B; Molvarec A; Takáts Z; Beko G; Rigó J; Vásárhelyi B
Clin Chem Lab Med; 2010 Oct; 48(10):1423-6. PubMed ID: 20626300
[TBL] [Abstract][Full Text] [Related]
19. Hepcidin and iron deficiency in pre-kidney transplant patients.
Sancho A; Pastor MC; Troya M; Bonal J; Bayés B; Morales-Indiano C; Lauzurica R; Romero R
Transplant Proc; 2009; 41(6):2079-81. PubMed ID: 19715836
[TBL] [Abstract][Full Text] [Related]
20. Is hepcidin-25 a clinically relevant parameter for the iron status in hemodialysis patients?
Brătescu LO; Bârsan L; Munteanu D; Stancu S; Mircescu G
J Ren Nutr; 2010 Sep; 20(5 Suppl):S77-83. PubMed ID: 20797577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
